Nature Biotechnology reports that FDA's push to reduce animal testing has fueled a boom in AI biosimulation and digital twin…
The startup behind AI molecule models used by Lilly, Novartis and Pfizer hits a $3.8 billion valuation.
The OpenADMET challenge found that smaller, specialized models matched or beat large foundation models at predicting how the body processes…
Transformer models outperform traditional methods in predicting antidepressant response from electronic health records, advancing precision psychiatry.
Google's TabFM is a foundation model for tabular data that makes accurate predictions on entirely new datasets without per-dataset fine-tuning,…
AI is reshaping pharmaceutical R&D from target identification through clinical trial optimization, compressing drug discovery timelines and unlocking therapeutic targets…
A new review in Nature Reviews Neurology examines the barriers preventing AI tools from moving from research labs into routine…